Protocol Ledger

NCT06856837 · Phase II · RECRUITING

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

Interventional Phase II clinical trial protocol NCT06856837 sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-10-27 Enrollment: 140 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06856837
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)140 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06856837
Protocol FieldVerified Registry Value
NCT IdentifierNCT06856837
Consolidated Lead SponsorInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment140 participants (ESTIMATED)
Registered Start Date2025-10-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06856837
Hospital Research SiteLocationSite Profile
Universitätsklinikum EssenEssen, GermanyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI